key: cord-0730032-zhd1vvaz
authors: Hughes-Visentin, Alexzandra; Paul, Anthea B Mahesan
title: Asthma and COVID-19: What do we know now
date: 2020-10-23
journal: Clin Med Insights Circ Respir Pulm Med
DOI: 10.1177/1179548420966242
sha: 048cfa5b79a0515283eb72a7d35be23f4a9b410e
doc_id: 730032
cord_uid: zhd1vvaz

The COVID-19 pandemic has presented challenges in symptomology identification, diagnosis, management and follow-up in common respiratory diseases, and in particular asthma. Research is rapidly ongoing to try and understand how the SARS-CoV-2 virus affects individuals with asthma, as well as, how underlying asthma affects Covid-19 risk, symptomology and prognosis. In light of this unique medical challenge, clinicians are faced with case-by-case based decisions to implement or continue current asthma therapy. This review will discuss the current literature regarding asthma and COVID-19 based on best available evidence at this time (See box 1).

Early evidence from Wuhan, China was inconclusive regarding the association of increased risk of COVID-19 infection in asthma patients. Several early case studies evaluating co-morbidities of inpatient adults with COVID-19 in Wuhan, China omitted asthma as a pre-existing comorbidity among their patient cohorts and thus a relationship was unable to be assessed. [1] [2] [3] Further, nationwide analysis of comorbidities and their impact on 1590 patients with COVID-19 in China found that none of the analyzed cases reported physician diagnosed asthma. 4 Following this Li et al. evaluated 584 patients admitted to hospital in Wuhan, China and found that reports of pre-existing asthma were markedly lower (0.9%, n = 5) than the general population (6.4%) and Zhang et al. who found a very low prevalence of 0.3% (n = 1) in their cohort of 290 COVID-positive patients. 5, 6 This was reciprocated in a systematic review of n = 12 760 individuals by Khan et al., which found 1.4% (n = 355) of their COVID-19 positive cohort had asthma as a comorbidity. 7 Other studies worldwide have demonstrated an increased prevalence of asthma in COVID-positive individuals and have suggested that the lower prevalence of asthma reported within some studies could be attributed to underreporting, underdiagnosis or poor recognition of chronic respiratory disease in patients with COVID-19 infection. 8 Additionally, another explanation for the differing rates of comorbid asthma seen among studies may be due to the overall differences in rates of comorbidities including asthma in different countries.

Kingdom have shown that patients with asthma are overrepresented among adult patients with COVID-19, who were admitted to hospital. [9] [10] [11] A study conducted by Chiba et al evaluated 1526 PCR confirmed Covid positive patients and found that 220 (14%) of patients had comorbid asthma. 12 However, comorbid asthma was not found to increase risk of hospitalization in this study population. 12 Recent data released from the Center for Disease Control and Prevention evaluated COVID-19 positive patients from several hospitals throughout the United States and showed that 27.3% of COVID-positive inpatients aged 18 to 49 years listed asthma as a comorbidity, with an incidence of 8.9% in the general population. 13, 14 Although studies have shown higher rates of comorbid asthma in COVID-19 positive patients, it was not specified whether asthma was allergic or non-allergic in origin. 15, 16 Zhu et al. found that once subcategorized, patients with allergic asthma had no statistically significant association with severe COVID-19 symptoms. 16 

Currently there are conflicting hypotheses surrounding the complex pathophysiology of asthma in positive COVID-19 patients and ongoing research is required. Theoretically, asthmatic patients are thought to have increased susceptibility and severity of COVID-19 due to decreased anti-viral immune response and increased risk of viral induced exacerbation. 17 However, interestingly it was hypothesized that type Asthma and COVID-19: What do we know now Alexzandra Hughes-Visentin 1 and Anthea B Mahesan Paul 2 2 Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine II inflammatory response cytokines (IL-4, -5 and -13) and accumulation of eosinophils seen in asthma may be protective against COVID-19. 17, 18 It is further hypothesized that the type II inflammatory response produced in the respiratory airway of patients with asthma is a protective factor against COVID-19. SARS-Cov-2 uses angiotensin converting enzyme 2 (ACE2) as its cellular receptor, similar to SARS and other seasonal coronaviruses. 15, 19 Therefore, increased expression of ACE2 is suspected to increase susceptibility to COVID-19. The respiratory epithelial cells in patients with asthma have decreased gene expression for ACE2 receptors and therefore may be protective against COVID-19 infection. 15, 17, 19 Nonallergic asthma was not associated with this change. 15 It was also found that type II inflammation is associated with increased TMPRSS2, a protease that allows for effective viral receptor binding, gene expression. 19 However, it is hypothesized that the decrease in ACE2 gene expression overrides the minimal increase in TMPRSS2 gene expression, potentially making asthma associated type II inflammation a protective factor against COVID-19. 16, 17, 19, 20 Additionally, eosinopenia has been observed in patients with COVID-19, and more prominently this was represented in the more severe cases, stabilizing after clinical improvement. 17, 21, 22 This suggests that eosinophils could play a protective role against developing more severe clinical outcomes. 21, 22 In contrast, it has also been proposed that asthma associated type II inflammatory response decreases host anti-viral immunity. 23, 24 In addition, asthma induced mucus plugging in the lower respiratory tract, limits airflow which could worsen the hypoxaemia from diffuse alveolar damage caused by COVID-19 infection. 25 Poor asthma control is a risk factor for more severe virus-induced exacerbations. 15, 24, 26 Viral infections, including several coronavirus species, have been shown to trigger asthma exacerbations, contribute to airway inflammation and mucus hypersecretion. 27 However, both SARS and MERS, similar species of coronavirus, were not shown to increase the risk of asthma exacerbation whereas, seasonal coronaviruses do increase this risk. 28 Grandbastien et al found that SARS-Cov-2 infection did not increase severe exacerbations in asthmatic patients. 22 However, similar to other coronaviruses, it is also hypothesized that SARS-Cov-2 will precipitate asthma exacerbation. 27 Therefore, further investigation into the immunopathological mechanism still needs to be elucidated to determine risk of severe exacerbations in asthmatic patients. 27 It is for these reasons among others that it is recommended that asthmatic patients continue their maintenance medications throughout the pandemic. 24 

Inhaled corticosteroids (ICS) are a common and effective first line treatment for control of asthma which allows steroids to be applied directly to the respiratory epithelium, allowing for rapid suppression of the airway epithelium inflammation through increasing anti-inflammatory cytokine levels. Several studies hypothesize the type II inflammatory response that occurs in the lungs due to asthma suppresses anti-viral immunity, therefore an inhaled corticosteroid will help to reduce this inflammation and subsequently increase anti-viral immunity. 23, 24, 27, 30 Additionally, early studies have shown that ICS may decrease both ACE2 and TMPRSS2 gene expression on respiratory epithelial cells, decreasing susceptibility of SARS-Cov-2 viral binding to receptors on respiratory epithelium. 20, 31, 32 Inhaled corticosteroids alone or in combination with bronchodilators have been shown to suppress coronavirus replication and cytokine production. 8, 33, 34 Interestingly, in an in vivo study, Matsuyama et al. found that ciclesonide, an inhaled corticosteroid selectively suppressed human coronavirus replication in human cultured cells. 33 Additionally, in vitro studies have shown that formoterol, glycopyrronium, and a combination of formoterol, glycopyrronium and budesonide, have inhibitory effects on seasonal coronavirus replication and cytokine production. 35 Further, although corticosteroids are not a mainstay treatment for lung injury caused by COVID-19, it has been suggested they may be beneficial in suppressing the pro-inflammatory cytokine release syndrome associated with the third phase of COVID-19 symptomology. 36 Patients that were given early, low-dose, short-term ICS experienced shorter duration of supplemental oxygen, decreased patient mortality, and improvement of clinical symptoms. 36, 37 Finally, systemic corticosteroids, such as prednisone, should be used to treat severe asthma exacerbations regardless of whether evoked by COVID-19 infection or another cause. 29 Leukotriene receptor antagonists act as an effective add on therapy for asthma control by promoting anti-inflammatory and bronchodilator effects in the respiratory tract. In preclinical models of viral influenza and acute respiratory distress syndrome, Montelukast has been shown to decrease both lung inflammation and cytokine release. 47 Montelukast was also shown to reduce eosinophilic inflammation in upper airway inflammatory disease by inhibiting epithelial cell cytokine release and promoting eosinophil survival. 47 Bozek et al. found that the rate of Covid-19 infection was significantly lower in a population of elderly patients with severe asthma taking Montelukast, compared to a similar population not taking the drug. 42 Of the hospitalized patients with Covid-19, those taking Montelukast, did not need respiratory therapy or multidrug antiviral treatment. 42 Additionally, Khan et al. found that Covid-19 positive patients that were treated with Montelukast experienced significantly fewer events of clinical deterioration that those not receiving the treatment. 47 Azithromycin has been shown to be an effective treatment in patients with asthma not adequately controlled by standard inhaler therapy, by decreasing exacerbation frequency and improving quality of life. 45 Additionally, treating asthmatic patients with azithromycin significantly increases IFN production, a cytokine associated with innate antiviral immunity, by respiratory cells and therefore may be effective at reducing risk of severe COVID-19 outcomes. 24 However, this treatment is not recommended as a preventative measure against Covid-19 infection. 48 Allergen immunotherapy (AIT) is a disease modifying therapy for allergic airway diseases, including asthma, whereby immune tolerance towards a specific allergen is developed, through repeated allergen administration. 46, 49 AIT treatment in asthmatic patients leads to a desensitization effect and immune tolerance which may be protective against cytokine storms occurring in severe Covid cases. 17 AIT treatment can be continued in asthmatic patients without clinical symptoms of Covid-19 or recent exposure to SARS-Cov-2 virus. 46 However, it is recommended that AIT immunotherapy be temporarily interrupted if patient becomes infected with an acute respiratory tract infection, including Covid-19, until infection is resolved. 46 Biologics are also used as an add on maintenance treatment for asthma, to reduce the frequency of severe asthma exacerbations. Monoclonal antibodies should be continued in asthmatic patients during the pandemic in order to prevent urgent physician and emergency department visits and hospitalization. If biological therapies are stopped then other medications should be given, such as low dose prednisone, high dose inhaled corticosteroids with long acting beta-2 agonist therapy or long-acting muscarinic therapy, to prevent exacerbations. 30 • In vitro studies have shown that formoterol has an inhibitory effect on seasonal coronavirus replications and cytokine production. 35 • Additive inhibitory effects on viral replication and cytokine production were shown when formoterol was used in combination with glycopyrronium and budesonide. 35 Anti-muscarinic • If biologic therapies are stopped then other medications should be given, such as low dose prednisone, high dose inhaled corticosteroids with long acting beta2 agonist therapy or long-acting muscarinic therapy, to prevent exacerbations. 29 • Omalizumab was shown to possibly be protective against viral induced asthma exacerbations. 29, 44 • Immune response to viral agents not suspected to be affected by the use of biologics for the treatment of asthma. 29 Azithromycin • Useful when asthma is uncontrolled by standard inhaler therapy. 24 • Proposed effects on anti-viral immunity, decreasing exacerbation frequency and improving quality of life. 24 • If asthma is not controlled by standard therapies, starting azithromycin prophylaxis therapy could be an acceptable treatment approach. 45 • Significantly increases IFN production, a cytokine associated with innate antiviral immunity, by respiratory cells and therefore may be effective at reducing risk of severe Covid-19 outcomes. 24 Allergen Immunotherapy physicians should also encourage self-administered biologic treatment at home if possible, to reduce office visits and help prevent patients from missing their scheduled doses. 20 Appropriate training sessions and in person physician demonstrations are needed to help patients transition from clinic to home administration and prevent unnecessary side effects of biologic injections. Biological therapies should be stopped temporarily if patient develops active COVID-19 and should not be continued again until patient is clinically asymptomatic and receives a negative Covid test swab. 21 Aerosolized devices are crucial for treatment administration in patients with respiratory illnesses, including asthma. 50 Metered-dose inhalers are ideal devices for treatment administration in many patients as they have a short treatment time, allow for multiple dose administrations and are easy to use. 50 This device has a low risk of viral transmission, however, may not be ideal for patients in acute life-threatening respiratory failure, with cognitive or neuromuscular impairment, or inadequate inspiratory strength. 50 Dry-powdered inhalers are driven into the lungs during inhalation and therefore do not require hand-breathe coordination. 50 However, dry-powdered inhalers can cause irritation to the airway causing cough and subsequently increasing risk of potential viral transmission. 50 Finally, nebulizers are more powerful devices that are associated with longer treatment times and require more maintenance. 50, 51 There is conflicting evidence on the risk of viral aerosolization with the use of nebulizer devices. Wan et al. found that the use of nebulizers in patients with SARS did not increase the risk of transmission of viral particles in a health care setting. 52 However, many hospitals have created strict guidelines surrounding the use of nebulizers in hospital, to decrease the risk of viral aerosolization among patients and health care providers. 51 Recommendations have been made to avoid nebulizer medications during the pandemic. Instead a metered-dose inhaler with a valved holding chamber or dry powdered inhaler are preferred to reduce auto-aerosolization and spread of virus into the surrounding environment. 9, 29 Patients currently on nebulized medications should continue on these medications only until their provider can discuss with them the alternative medication options. 29

Recommendations have been made from several national and international societies on the management of asthma during the pandemic. These recommendations are consistent and recommend staying on the same maintenance and exacerbation medications during the COVID-19 pandemic. 29, 30, 40, 53 It is also recommended to take additional precautions including avoiding asthma exacerbation triggers, ensuring proper inhaler techniques, maintaining physical distancing and practicing Biologic therapy + -Continue in Covid -ve asthmatic patients for which treatment is indicated and effective. 29 proper hand hygiene. 53 It is not recommended to step down from any current asthma management plans, unless proven beneficial to a specific patient's situation. 40 Additionally, the use of telemedicine has rapidly progressed since the onset of the Covid-19 pandemic in an effort to reduce unnecessary in person medical visits. 54, 55 Due to this many allergy and immunology clinicians have had to rapidly incorporate telemedicine into their practices. 54, 55 A recent metaanalysis found that both tele-case management and tele-consultation were effective telemedicine tools in improving asthma control and quality of life in adult patients. 56 Additionally, telemedicine was shown to be non-inferior to inperson consultations for asthma treatment and management. 54 Clinicians should take into account individualized patient circumstances when choosing between in-person and telemedicine consultations for the diagnosis and treatment of asthma. 55

Recommendations have been made by many regulatory bodies to place restrictions on pulmonary function testing for the monitoring and diagnosis of respiratory illnesses. 57, 58 Pulmonary function testing should be limited to spirometry, oximetry, and arterial blood gases and testing should only be performed on patients if essential for immediate treatment decisions. 58 These restrictions may lead to delayed diagnosis in non-severe asthmatic patients. Additionally, screening protocols have now become mandatory prior to entry into several workplaces. This may pose a burden to individuals with asthma due to the similarity in symptom profiles, such as shortness of breath and cough. This could potentially restrict these individuals from being present at work during periods of asthma exacerbations and subsequently have potential downstream impacts on vocational success.

Recently there has been a reported shortage of metereddose inhaler quick relief medications in Canada, the United States and Australia. This is multi-factorial including the recent increase proportion of patients switching to metereddose treatments from nebulized treatments since the later increases risk of viral aerosolization and viral transmission. 59 In addition, several countries have put restrictions on prescription medication, such as bronchodilators, to reduce unnecessary stockpiling of these medications. In asthmatic patients, this reduced availability of routine medications and fear of visiting crowded emergency facilities could result in an increase of asthmatic morbidity in the general public. Education to reduce exposure to asthma triggers, hand washing, and social distancing is essential to reduce the burden on this population.

To the best of our knowledge there currently is no evidence whether having COVID-19, will increase severity of asthma exacerbations long-term in adult patients. Further studies need to be done investigating the long-term effects of past COVID-19 infection on asthma disease progression.

Both listed authors made a substantial contribution to the concept or design of the work; or acquisition, analysis or interpretation of data; Drafted the article or revised it critically for important intellectual content; Approved the version to be published and are in agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Anthea B Mahesan Paul https://orcid.org/0000-0002 -6463-6011

Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan

Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study

Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China

Clinical characteristics of coronavirus disease 2019 in China

Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan

Distinct characteristics of COVID-19 patients with initial rRT-PCR-positive and rRT-PCR-negative results for SARS-CoV-2

Effects of preexisting morbidities on occurrence of death among COVID-19 disease patients: a systematic review and meta-analysis. medRxiv

Do chronic respiratory diseases or their treatment affect the risk of SARS-CoV-2 infection?

Asthma and COVID-19

Covid-19 in critically ill patients in the Seattle region -case series

Features of 16,749 hospitalised UK patients with COVID-19 using the ISARIC WHO clinical characterisation protocol. medRxiv

Prevalence and characterization of asthma in hospitalized and nonhospitalized patients with COVID-19

Preliminary estimates of the prevalence of selected underlying health conditions among patients with coronavirus disease 2019-United States

Hospitalization rates and characteristics of patients hospitalized with laboratory-confirmed coronavirus disease 2019-COVID-NET, 14 States

Association of respiratory allergy, asthma, and expression of the SARS-CoV-2 receptor ACE2

Association of asthma and its genetic predisposition with the risk of severe COVID-19

COVID-19 and asthma: reflection during the pandemic

Is asthma protective against COVID-19? Allergy

Type 2 and interferon inflammation strongly regulate SARS-CoV-2 related gene expression in the airway epithelium

COVID-19, asthma, and biological therapies: what we need to know

Considerations on biologicals for patients with allergic disease in times of the COVID-19 pandemic: an EAACI statement

SARS-CoV-2 pneumonia in hospitalized asthmatic patients did not induce severe exacerbation

Managing childhood allergies and immunodeficiencies during respiratory virus epidemics -The 2020 COVID-19 pandemic: a statement from the EAACI-section on pediatrics

Asthma and COVID-19: is asthma a risk factor for severe outcomes?

Postmortem lung findings in a patient with asthma and coronavirus disease 2019

Eleven faces of coronavirus disease 2019

Treatment of COVID-19-exacerbated asthma: should systemic corticosteroids be used?

Asthma increases risk of severity of COVID-19

Addressing therapeutic questions to help Canadian physicians optimize asthma management for their patients during the COVID-19 pandemic

Key highlights from the Canadian Thoracic Society position statement on the optimization of asthma management during the coronavirus disease 2019 pandemic

Inhaled corticosteroids and COVID-19: a systematic review and clinical perspective

COVID-19-related genes in sputum cells in asthma. Relationship to demographic features and corticosteroids

The inhaled corticosteroid ciclesonide blocks coronavirus RNA replication by targeting viral NSP15

Therapeutic potential of ciclesonide inahalation for COVID-19 pneumonia: Report of three cases

Inhibitory effects of glycopyrronium, formoterol, and budesonide on coronavirus HCoV-229E replication and cytokine production by primary cultures of human nasal and tracheal epithelial cells

Case study: a patient with asthma, Covid-19 pneumonia and cytokine release syndrome treated with corticosteroids and tocilizumab

Early, low-dose and short-term application of corticosteroid treatment in patients with severe COVID-19 pneumonia: singlecenter experience from Wuhan, China. medRxiv

On the use of corticosteroids for 2019-nCoV pneumonia

Corticosteroid therapy for critically ill patients with Middle East respiratory syndrome

COVID-19: Pandemic contingency planning for the allergy and immunology clinic

Leukotriene receptor antagonist therapy

Montelukast's ability to fight COVID-19 infection

The mode of action of anticholinergics in asthma

Effects of omalizumab on rhinovirus infections, illnesses, and exacerbations of asthma

A compendium answering 150 questions on COVID-19 and SARS-CoV-2

Handling of allergen immunotherapy in the COVID-19 pandemic: an ARIA-EAACI statement

Montelukast in hospitalized patients diagnosed with COVID-19

Safety of hydroxychloroquine, alone and in combination with azithromycin, in light of rapid wide-spread use for COVID-19: a multinational, network cohort and self-controlled case series study

Impact of allergen immunotherapy in allergic asthma

Promoting safe and effective use of aerosol devices in COVID-19: risks and suggestions for viral transmission

Transmission of coronavirus by nebulizer: a serious, underappreciated risk

A large-volume nebulizer would not be an infectious source for severe acute respiratory syndrome

Managing asthma during coronavirus disease-2019: an example for other chronic conditions in children and adolescents

Telemedicine in the era of COVID-19

COVID-19: unmasking telemedicine

The effects of telemedicine on asthma control and patients' quality of life in adults: a systematic review and meta-analysis

Practical considerations for spirometry during the COVID-19 outbreak: literature review and insights

Sleep labs, lung function tests and COVID-19 pandemic-only emergencies allowed! Pulmonology

Risk communication during COVID-19